Ublituximab

Briumvi 150 MG Concentrado Para Solucion Para Perfusion

150 mg concentrado para solución para perfusiónSpainMarketedAuthorised 14 Nov 2023

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BriumviEuropean UnionAuthorised

BriumviBrazil · Neuraxpharm Brasil Importacao e Distribuicao de Medicamentos Ltda.Same brand
BriumviEuropean Union · Neuraxpharm Pharmaceuticals S.L.Same brand
BriumviCroatiaSame brand
BriumviItaly · Concentrato per soluzione per infusione · Neuraxpharm Pharmaceuticals, S.LSame brand
Briumvi 150 mg concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Neuraxpharm Pharmaceuticals S.L.Same brand
BriumviUnited States · 25 MG/ML · injectable · TG Therapeutics, INC

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ublituximab

Briumvi 150 MG Concentrado Para Solucion Para Perfusion

150 mg concentrado para solución para perfusiónSpainMarketedAuthorised 14 Nov 2023

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BriumviEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Packs

Pack	Code	Status
BRIUMVI 150 MG CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial	763751

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ublituximab
Strength: 150 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 14 Nov 2023
Registration: 1231730001
Marketing authorisation holder: Neuraxpharm Pharmaceuticals S.L.
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/23/1730